Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta

23 Feb 2021

Abstract excerpt

The majority of patients with high-risk neuroblastoma (HR-NB) in low- and middle-income countries (LMIC) do not have access to autologous stem cell transplant (ASCT) and dinutuximab. Consolidation with nonmyeloablative chemotherapy is not well-defined, and the outcomes are variable. We report a single-center outcome of patients with HR-NB, treated with nonmyeloablative consolidation. A tabulated compilation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33622164
DOI: 10.1080/08880018.2020.1850955

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab betaPMID 33622164Read ↗

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Semantic proximity Read ↗

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk NeuroblastomaSemantic proximity Read ↗

Investigational drugs in phase II clinical trials for the treatment of neuroblastomaSemantic proximity Read ↗

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastomaSemantic proximity Read ↗

Survival of high‐risk pediatric neuroblastoma patients in a developing countrySemantic proximity Read ↗

Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective TreatmentSemantic proximity Read ↗

Cancer stem cells in neuroblastoma therapy resistanceSemantic proximity Read ↗

Risk of Developing Second Malignant Neoplasms in Patients with Neuroblastoma: A Population Study of the US SEER DatabaseSemantic proximity Read ↗

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531Semantic proximity Read ↗

Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of SMC NB-2004 studySemantic proximity Read ↗

Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastomaSemantic proximity Read ↗

High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.